SUMMIT, N.J.--(BUSINESS WIRE)--The New England Journal of Medicine today published updated clinical data from a Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered, randomized, double-blind, placebo-controlled Phase III pivotal study evaluating lenalidomide plus dexamethasone in previously treated multiple myeloma patients
